| Norah Khangura, | |
|
36500 Aurora Dr, Summit, WI 53066-4899 | |
| (262) 434-1000 | |
| Not Available |
| Full Name | Norah Khangura |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 21 Years |
| Location | 36500 Aurora Dr, Summit, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275861080 | NPI | - | NPPES |
| 100032496 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 39670 (Iowa) | Secondary |
| 207W00000X | Ophthalmology | 61175 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Medical Center - Summit | Summit, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
Hearing aids for as many as ten million Americans living with untreated hearing loss could soon become a reality if Congress acts, according to Stephen Hansbrough, CEO of HearUSA (Amex: EAR), one of the nation's largest hearing care companies.
Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa to help improve the healthcare and health-related education infrastructure in Africa.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Nanotechnology-based compounds are now being tested as a possible delivery vehicle for vaccines. A team of researchers demonstrated how the oral delivery vehicle SBA-15, one such nanotechnology-based compound can deliver an oral vaccine against hepatitis B to the immune system.
New strategies are needed to fight malaria in countries with low prevalence, because "pockets of infection remain, mainly among men living or working outdoors," according to a paper published in The Lancet, BBC News reports.
› Verified 3 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Hearing aids for as many as ten million Americans living with untreated hearing loss could soon become a reality if Congress acts, according to Stephen Hansbrough, CEO of HearUSA (Amex: EAR), one of the nation's largest hearing care companies.
Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa to help improve the healthcare and health-related education infrastructure in Africa.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Nanotechnology-based compounds are now being tested as a possible delivery vehicle for vaccines. A team of researchers demonstrated how the oral delivery vehicle SBA-15, one such nanotechnology-based compound can deliver an oral vaccine against hepatitis B to the immune system.
New strategies are needed to fight malaria in countries with low prevalence, because "pockets of infection remain, mainly among men living or working outdoors," according to a paper published in The Lancet, BBC News reports.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Norah Khangura, Po Box 735044, Chicago, IL 60673-5044 Ph: () - | Norah Khangura, 36500 Aurora Dr, Summit, WI 53066-4899 Ph: (262) 434-1000 |
News Archive
Hearing aids for as many as ten million Americans living with untreated hearing loss could soon become a reality if Congress acts, according to Stephen Hansbrough, CEO of HearUSA (Amex: EAR), one of the nation's largest hearing care companies.
Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa to help improve the healthcare and health-related education infrastructure in Africa.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Nanotechnology-based compounds are now being tested as a possible delivery vehicle for vaccines. A team of researchers demonstrated how the oral delivery vehicle SBA-15, one such nanotechnology-based compound can deliver an oral vaccine against hepatitis B to the immune system.
New strategies are needed to fight malaria in countries with low prevalence, because "pockets of infection remain, mainly among men living or working outdoors," according to a paper published in The Lancet, BBC News reports.
› Verified 3 days ago
Dr. Kimberly Couture Ireland, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 36500 Aurora Dr, Summit, WI 53066 Phone: 262-434-5000 Fax: 262-434-5000 | |
Jihan Akhtar Bhikhapurwala, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 36500 Aurora Dr, Summit, WI 53066 Phone: 262-434-1000 | |
Dr. Spencer William Rogers, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 36500 Aurora Dr, Summit, WI 53066 Phone: 262-434-5000 |